Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Interest Coverage : 0 (At Loss) (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Reviva Pharmaceuticals Holdings Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Reviva Pharmaceuticals Holdings's Operating Income for the three months ended in Mar. 2024 was $-7.92 Mil. Reviva Pharmaceuticals Holdings's Interest Expense for the three months ended in Mar. 2024 was $-0.00 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Reviva Pharmaceuticals Holdings's Interest Coverage or its related term are showing as below:

RVPH's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 145.09
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Reviva Pharmaceuticals Holdings Interest Coverage Historical Data

The historical data trend for Reviva Pharmaceuticals Holdings's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Reviva Pharmaceuticals Holdings Interest Coverage Chart

Reviva Pharmaceuticals Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

No Debt

Reviva Pharmaceuticals Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Coverage	Get a 7-Day Free Trial													-	-	-	No Debt	-

Competitive Comparison of Reviva Pharmaceuticals Holdings's Interest Coverage

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reviva Pharmaceuticals Holdings's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's Interest Coverage falls into.

Reviva Pharmaceuticals Holdings Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Reviva Pharmaceuticals Holdings's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Reviva Pharmaceuticals Holdings's Interest Expense was $0.00 Mil. Its Operating Income was $-39.50 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Reviva Pharmaceuticals Holdings had no debt ⁽¹⁾.

Reviva Pharmaceuticals Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Reviva Pharmaceuticals Holdings's Interest Expense was $-0.00 Mil. Its Operating Income was $-7.92 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Reviva Pharmaceuticals Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Reviva Pharmaceuticals Holdings (NAS:RVPH) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Reviva Pharmaceuticals Holdings Interest Coverage Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPH) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014

Website

https://www.revivapharma.com

Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.

Executives

Purav Patel	director	19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Narayan Parbhu	officer: Chief Financial Officer	19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA 95014
Beta Operators Fund, L.p.	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates, L.p.	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Partners, Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates-r, Lp	10 percent owner	250 WEST 55TH STREET, STE 13D, NEW YORK NY 10019
Parag Saxena	director, 10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Rahul Nayar	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Tenzing Llc	director, 10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Laxminarayan Bhat	director, 10 percent owner, officer: President and CEO	19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Leslie D. Funtleyder	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Marc Cantillon	officer: Chief Medical Officer	19925 STEVENS CREEK BLVD., SUITE 100, CUPPERTINO CA 95014
Richard A Margolin	director	19925 STEVENS CREEK BLVD, SUITE 100, CUPPERTINO CA 95014
Glazer Capital, Llc	10 percent owner	250 WEST 55TH STREET, SUITE 30A, NEW YORK NY 10019
Paul J Glazer	10 percent owner	250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019